The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) drugs in development market research report provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued products.

GlobalData tracks 32 drugs in development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) by 29 companies/universities/institutes. The top development phase for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) is phase ii with 22 drugs in that stage. The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) pipeline has 32 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) pipeline products market are: Mirati Therapeutics, Tango Therapeutics and Bristol-Myers Squibb.

The key targets in the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Protein Arginine N Methyltransferase 5 (Shk1 Kinase Binding Protein 1 Homolog or Jak Binding Protein 1 or Histone Arginine N Methyltransferase PRMT5 or 72 kDa ICln Binding Protein or PRMT5 or EC 2.1.1.320), and Mast/Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or CD117 or KIT or EC 2.7.10.1).

The key mechanisms of action in the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with four drugs in Phase III. The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) pipeline products include ten routes of administration with the top ROA being Oral and five key molecule types in the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) pipeline products market including Small Molecule, and Monoclonal Antibody.

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) overview

Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas that originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include a lump or swelling in the in the soft tissue, numbness, burning, tingling or pins and needles, weakness of the affected muscles, and dizziness or loss of balance. Treatment includes surgery, radiotherapy, and chemotherapy.

For a complete picture of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.